JohnMoehrke Consent with Segmented data
0.1.0-current - ci-build International flag

JohnMoehrke Consent with Segmented data, published by John Moehrke (himself). This guide is not an authorized publication; it is the continuous build for version 0.1.0-current built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/JohnMoehrke/ConsentWithSegmentation/ and changes regularly. See the Directory of published versions

ValueSet: clinical codes that indicate HIV

Official URL: http://johnmoehrke.github.io/ConsentWithSegmentation/ValueSet/SlsSensitiveHIV Version: 0.1.0-current
Standards status: Draft Maturity Level: 0 Computable Name: SlsSensitiveHIV

HIV/AIDS information

  • SAMSHA C2S HIV/AIDS Information
    • ValueSet 2.16.840.1.113762.1.4.1142.23 // HCPCS
    • ValueSet 2.16.840.1.113762.1.4.1142.24 // ICD9CM
    • ValueSet 2.16.840.1.113762.1.4.1142.25 // LOINC
    • ValueSet 2.16.840.1.113762.1.4.1142.26 // RXNORM
    • ValueSet 2.16.840.1.113762.1.4.1142.27 // SNOMED-CT
    • ValueSet 2.16.840.1.113762.1.4.1142.60 // CPT
  • SAMSHA Test C2S HIV/AIDS Information Sensitivity
    • ValueSet 2.16.840.1.113762.1.4.1142.67 // SNOMEDCD

References

This value set is not used here; it may be used elsewhere (e.g. specifications and/or implementations that use this content)

Logical Definition (CLD)

This value set includes codes based on the following rules:

 

Expansion

This value set contains 162 concepts

SystemVersionCodeDisplay (en)JSONXML
http://www.nlm.nih.gov/research/umls/hcpcs2022  0575FHiv rna control plan of care, documented (hiv)
http://www.nlm.nih.gov/research/umls/hcpcs2022  3292FHiv testing ordered or documented and reviewed during the first or second prenatal visit (pre-cr)
http://www.nlm.nih.gov/research/umls/hcpcs2022  3490FHistory of aids-defining condition (hiv)
http://www.nlm.nih.gov/research/umls/hcpcs2022  3491FHiv indeterminate (infants of undetermined hiv status born of hiv-infected mothers) (hiv)
http://www.nlm.nih.gov/research/umls/hcpcs2022  3492FHistory of nadir cd4+ cell count <350 cells/mm (hiv)
http://www.nlm.nih.gov/research/umls/hcpcs2022  3493FNo history of nadir cd4+ cell count <350 cells/mmand no history of aids-defining condition (hiv)
http://www.nlm.nih.gov/research/umls/hcpcs2022  3494FCd4+ cell count <200 cells/mm3 (hiv)
http://www.nlm.nih.gov/research/umls/hcpcs2022  3495FCd4+ cell count 200 - 499 cells/mm3 (hiv)
http://www.nlm.nih.gov/research/umls/hcpcs2022  3496FCd4+ cell count >=500 cells/mm3 (hiv)
http://www.nlm.nih.gov/research/umls/hcpcs2022  3497FCd4+ cell percentage <15% (hiv)
http://www.nlm.nih.gov/research/umls/hcpcs2022  3498FCd4+ cell percentage >/=15% (hiv)
http://www.nlm.nih.gov/research/umls/hcpcs2022  3500FCd4+ cell count or cd4+ cell percentage documented as performed (hiv)
http://www.nlm.nih.gov/research/umls/hcpcs2022  3502FHiv rna viral load below limits of quantification (hiv)
http://www.nlm.nih.gov/research/umls/hcpcs2022  3503FHiv rna viral load not below limits of quantification (hiv)
http://www.nlm.nih.gov/research/umls/hcpcs2022  3510FDocumentation that tuberculosis (tb) screening test performed and results interpreted (hiv) (ibd)
http://www.nlm.nih.gov/research/umls/hcpcs2022  3511FChlamydia and gonorrhea screenings documented as performed (hiv)
http://www.nlm.nih.gov/research/umls/hcpcs2022  3512FSyphilis screening documented as performed (hiv)
http://www.nlm.nih.gov/research/umls/hcpcs2022  3513FHepatitis b screening documented as performed (hiv)
http://www.nlm.nih.gov/research/umls/hcpcs2022  3514FHepatitis c screening documented as performed (hiv)
http://www.nlm.nih.gov/research/umls/hcpcs2022  3515FPatient has documented immunity to hepatitis c (hiv)
http://www.nlm.nih.gov/research/umls/hcpcs2022  4149FHepatitis b vaccine injection administered or previously received (hep-c, hiv) (ibd)
http://www.nlm.nih.gov/research/umls/hcpcs2022  4270FPatient receiving potent antiretroviral therapy for 6 months or longer (hiv)
http://www.nlm.nih.gov/research/umls/hcpcs2022  4271FPatient receiving potent antiretroviral therapy for less than 6 months or not receiving potent antiretroviral therapy (hiv)
http://www.nlm.nih.gov/research/umls/hcpcs2022  4274FInfluenza immunization administered or previously received (hiv) (p-esrd)
http://www.nlm.nih.gov/research/umls/hcpcs2022  4276FPotent antiretroviral therapy prescribed (hiv)
http://www.nlm.nih.gov/research/umls/hcpcs2022  4279FPneumocystis jiroveci pneumonia prophylaxis prescribed (hiv)
http://www.nlm.nih.gov/research/umls/hcpcs2022  4280FPneumocystis jiroveci pneumonia prophylaxis prescribed within 3 months of low cd4+ cell count or percentage (hiv)
http://www.nlm.nih.gov/research/umls/hcpcs2022  4290FPatient screened for injection drug use (hiv)
http://www.nlm.nih.gov/research/umls/hcpcs2022  4293FPatient screened for high-risk sexual behavior (hiv)
http://www.nlm.nih.gov/research/umls/hcpcs2022  86689Confirmation test for antibody to Human T-cell lymphotropic virus (HTLV) or HIV
http://www.nlm.nih.gov/research/umls/hcpcs2022  86701Analysis for antibody to HIV -1 virus
http://www.nlm.nih.gov/research/umls/hcpcs2022  86702Analysis for antibody to HIV-2 virus
http://www.nlm.nih.gov/research/umls/hcpcs2022  86703Analysis for antibody to HIV-1 and HIV-2 virus
http://www.nlm.nih.gov/research/umls/hcpcs2022  87389Detection test by immunoassay technique for HIV-1 antigen and HIV-1 and HIV-2 antibodies
http://www.nlm.nih.gov/research/umls/hcpcs2022  87390Detection test by immunoassay technique for HIV-1 antigen
http://www.nlm.nih.gov/research/umls/hcpcs2022  87391Detection test by immunoassay technique for HIV-2 antigen
http://www.nlm.nih.gov/research/umls/hcpcs2022  87534Detection test by nucleic acid for HIV-1 virus, direct probe technique
http://www.nlm.nih.gov/research/umls/hcpcs2022  87535Detection test by nucleic acid for HIV-1 virus, amplified probe technique
http://www.nlm.nih.gov/research/umls/hcpcs2022  87536Detection test by nucleic acid for HIV-1 virus, quantification
http://www.nlm.nih.gov/research/umls/hcpcs2022  87537Detection test by nucleic acid for HIV-2 virus, direct probe technique
http://www.nlm.nih.gov/research/umls/hcpcs2022  87538Detection test by nucleic acid for HIV-2 virus, amplified probe technique
http://www.nlm.nih.gov/research/umls/hcpcs2022  87539Detection test by nucleic acid for HIV-2 virus, quantification
http://www.nlm.nih.gov/research/umls/hcpcs2022  87900Infectious agent drug susceptibility analysis
http://www.nlm.nih.gov/research/umls/hcpcs2022  87901Analysis test by nucleic acid for HIV-1 virus
http://www.nlm.nih.gov/research/umls/hcpcs2022  87903Analysis test by nucleic acid for HIV-1 virus, first through 10 drugs tested
http://www.nlm.nih.gov/research/umls/hcpcs2022  87904Analysis test by nucleic acid for HIV-1 virus, each additional drug tested
http://www.nlm.nih.gov/research/umls/hcpcs2022  87906Analysis test by nucleic acid for HIV-1 virus, other region
http://www.nlm.nih.gov/research/umls/hcpcs2022  G0432Infectious agent antibody detection by enzyme immunoassay (eia) technique, hiv-1 and/or hiv-2, screening
http://www.nlm.nih.gov/research/umls/hcpcs2022  G0433Infectious agent antibody detection by enzyme-linked immunosorbent assay (elisa) technique, hiv-1 and/or hiv-2, screening
http://www.nlm.nih.gov/research/umls/hcpcs2022  G0435Infectious agent antibody detection by rapid antibody test, hiv-1 and/or hiv-2, screening
http://www.nlm.nih.gov/research/umls/hcpcs2022  S3645Hiv-1 antibody testing of oral mucosal transudate
http://hl7.org/fhir/sid/icd-9-cm2013  136.3Pneumocystosis
http://hl7.org/fhir/sid/icd-9-cm2013  176.9Kaposi's sarcoma, unspecified site
http://hl7.org/fhir/sid/icd-9-cm2013  42Operations on esophagus
http://loinc.org2.72  10901-7HIV 2 gp125 Ab [Presence] in Serum by Immunoblot
http://loinc.org2.72  10902-5HIV 2 gp36 Ab [Presence] in Serum by Immunoblot
http://loinc.org2.72  11078-3HIV 2 gp80 Ab [Presence] in Serum by Immunoblot
http://loinc.org2.72  11079-1HIV 2 p26 Ab [Presence] in Serum by Immunoblot
http://loinc.org2.72  11080-9HIV 2 p53 Ab [Presence] in Serum by Immunoblot
http://loinc.org2.72  11081-7HIV 2 p56 Ab [Presence] in Serum by Immunoblot
http://loinc.org2.72  11082-5HIV 2 p68 Ab [Presence] in Serum by Immunoblot
http://loinc.org2.72  13920-4HIV 2 p41 Ab [Presence] in Serum by Immunoblot
http://loinc.org2.72  21334-8HIV 2 gp105 Ab [Presence] in Serum by Immunoblot
http://loinc.org2.72  21335-5HIV 2 gp120 Ab [Presence] in Serum by Immunoblot
http://loinc.org2.72  21336-3HIV 2 gp15 Ab [Presence] in Serum by Immunoblot
http://loinc.org2.72  21337-1HIV 2 gp34 Ab [Presence] in Serum by Immunoblot
http://loinc.org2.72  21338-9HIV 2 p31 Ab [Presence] in Serum by Immunoblot
http://loinc.org2.72  21339-7HIV 2 p55 Ab [Presence] in Serum by Immunoblot
http://loinc.org2.72  21340-5HIV 2 p58 Ab [Presence] in Serum by Immunoblot
http://loinc.org2.72  22358-6HIV 2 Ab [Units/volume] in Serum
http://loinc.org2.72  25841-8HIV 2 proviral DNA [Presence] in Blood by NAA with probe detection
http://loinc.org2.72  25842-6HIV 2 proviral DNA [Presence] in Specimen by NAA with probe detection
http://loinc.org2.72  30361-0HIV 2 Ab [Presence] in Serum or Plasma by Immunoassay
http://loinc.org2.72  31073-0HIV 2 Ab band pattern [Interpretation] in Serum by Immunoblot
http://loinc.org2.72  33806-1HIV 2 IgG Ab [Presence] in Serum by Immunoblot
http://loinc.org2.72  33807-9HIV 2 IgG Ab [Presence] in Serum
http://loinc.org2.72  34699-9HIV 2 proviral DNA [Presence] in Serum or Plasma by NAA with probe detection
http://loinc.org2.72  42768-2HIV 1 and 2 Ab [Interpretation] in Serum Narrative
http://loinc.org2.72  43185-8HIV 1 and 2 Ab band pattern [Interpretation] in Serum by Immunoblot
http://loinc.org2.72  45212-8HIV 2 p31+p34 Ab [Presence] in Serum by Immunoblot
http://loinc.org2.72  47029-4HIV 2 Ab [Presence] in Cerebral spinal fluid by Immunoblot
http://loinc.org2.72  51786-2HIV 2 Ab Signal/Cutoff in Serum or Plasma by Immunoassay
http://loinc.org2.72  5224-1HIV 2 Ab [Units/volume] in Serum or Plasma by Immunoassay
http://loinc.org2.72  5225-8HIV 2 Ab [Presence] in Serum by Immunoblot
http://loinc.org2.72  56888-1HIV 1+2 Ab+HIV1 p24 Ag [Presence] in Serum or Plasma by Immunoassay
http://loinc.org2.72  57976-3HIV 2 gp140 Ab [Presence] in Serum by Immunoblot
http://loinc.org2.72  57977-1HIV 2 p16 Ab [Presence] in Serum by Immunoblot
http://loinc.org2.72  57978-9HIV 2 p34 Ab [Presence] in Serum by Immunoblot
http://loinc.org2.72  58900-2HIV 1+2 Ab+HIV1 p24 Ag [Units/volume] in Serum or Plasma by Immunoassay
http://loinc.org2.72  62456-9HIV 2 p15 Ab [Presence] in Serum by Immunoblot
http://loinc.org2.72  6429-5HIV identified in Blood by Organism specific culture
http://loinc.org2.72  6430-3HIV identified in Semen by Organism specific culture
http://loinc.org2.72  6431-1HIV identified in Specimen by Organism specific culture
http://loinc.org2.72  69353-1HIV 2 RNA [Presence] in Serum or Plasma by NAA with probe detection
http://loinc.org2.72  69354-9HIV 2 RNA [Units/volume] (viral load) in Serum or Plasma by NAA with probe detection
http://loinc.org2.72  69668-2HIV 1 and 2 Ab [Identifier] in Serum or Plasma by Rapid immunoassay
http://loinc.org2.72  7919-4HIV 2 Ab [Presence] in Serum
http://loinc.org2.72  9836-8HIV proviral DNA [Presence] in Blood by Probe with amplification
http://loinc.org2.72  LP14307-0HIV 1
http://loinc.org2.72  LP16715-2HIV 1+2
http://loinc.org2.72  LP16716-0HIV 2
http://loinc.org2.72  LP29063-2HIV reverse transcriptase gene
http://loinc.org2.72  LP30901-0HIV protease gene
http://loinc.org2.72  LP32723-6HIV reverse transcriptase+protease gene
http://loinc.org2.72  LP36650-7HIV 1 & 2
http://loinc.org2.72  LP36876-8HIV nucleoside reverse transcriptase gene
http://loinc.org2.72  LP36877-6HIV nonnucleoside reverse transcriptase gene
http://loinc.org2.72  LP38420-3HIV identified
http://loinc.org2.72  LP38459-1HIV 1+2 Ab
http://loinc.org2.72  LP38463-3HIV 2 Ab
http://loinc.org2.72  LP62411-1HIV 1+O+2 Ab
http://www.nlm.nih.gov/research/umls/rxnorm09062022  152535Zovirax
http://www.nlm.nih.gov/research/umls/rxnorm09062022  281acyclovir
http://snomed.info/scthttp://snomed.info/sct/731000124108/version/20220301  111880001Acute human immunodeficiency virus infection (disorder)
http://snomed.info/scthttp://snomed.info/sct/731000124108/version/20220301  420721002Acquired immunodeficiency syndrome-associated disorder (disorder)
http://www.ama-assn.org/go/cpt2022  0575FHIV RNA control plan of care, documented (HIV)
http://www.ama-assn.org/go/cpt2022  3292FHIV testing ordered or documented and reviewed during the first or second prenatal visit (Pre-Cr)
http://www.ama-assn.org/go/cpt2022  3490FHistory of AIDS-defining condition (HIV)
http://www.ama-assn.org/go/cpt2022  3491FHIV indeterminate (infants of undetermined HIV status born of HIV-infected mothers) (HIV)
http://www.ama-assn.org/go/cpt2022  3492FHistory of nadir CD4+ cell count <350 cells/mm3 (HIV)
http://www.ama-assn.org/go/cpt2022  3493FNo history of nadir CD4+ cell count <350 cells/mm3 and no history of AIDS-defining condition (HIV)
http://www.ama-assn.org/go/cpt2022  3494FCD4+ cell count <200 cells/mm3 (HIV)
http://www.ama-assn.org/go/cpt2022  3495FCD4+ cell count 200 - 499 cells/mm3 (HIV)
http://www.ama-assn.org/go/cpt2022  3496FCD4+ cell count >/=500 cells/mm3 (HIV)
http://www.ama-assn.org/go/cpt2022  3497FCD4+ cell percentage <15% (HIV)
http://www.ama-assn.org/go/cpt2022  3498FCD4+ cell percentage >/=15% (HIV)
http://www.ama-assn.org/go/cpt2022  3500FCD4+ cell count or CD4+ cell percentage documented as performed (HIV)
http://www.ama-assn.org/go/cpt2022  3502FHIV RNA viral load below limits of quantification (HIV)
http://www.ama-assn.org/go/cpt2022  3503FHIV RNA viral load not below limits of quantification (HIV)
http://www.ama-assn.org/go/cpt2022  3510FDocumentation that tuberculosis (TB) screening test performed and results interpreted (HIV) (IBD)
http://www.ama-assn.org/go/cpt2022  3511FChlamydia and gonorrhea screenings documented as performed (HIV)
http://www.ama-assn.org/go/cpt2022  3512FSyphilis screening documented as performed (HIV)
http://www.ama-assn.org/go/cpt2022  3513FHepatitis B screening documented as performed (HIV)
http://www.ama-assn.org/go/cpt2022  3514FHepatitis C screening documented as performed (HIV)
http://www.ama-assn.org/go/cpt2022  3515FPatient has documented immunity to Hepatitis C (HIV)
http://www.ama-assn.org/go/cpt2022  4149FHepatitis B vaccine injection administered or previously received (HEP-C, HIV) (IBD)
http://www.ama-assn.org/go/cpt2022  4270FPatient receiving potent antiretroviral therapy for 6 months or longer (HIV)
http://www.ama-assn.org/go/cpt2022  4271FPatient receiving potent antiretroviral therapy for less than 6 months or not receiving potent antiretroviral therapy (HIV)
http://www.ama-assn.org/go/cpt2022  4274FInfluenza immunization administered or previously received (HIV) (P-ESRD)
http://www.ama-assn.org/go/cpt2022  4276FPotent antiretroviral therapy prescribed (HIV)
http://www.ama-assn.org/go/cpt2022  4279FPneumocystis jiroveci pneumonia prophylaxis prescribed (HIV)
http://www.ama-assn.org/go/cpt2022  4280FPneumocystis jiroveci pneumonia prophylaxis prescribed within 3 months of low CD4+ cell count or percentage (HIV)
http://www.ama-assn.org/go/cpt2022  4290FPatient screened for injection drug use (HIV)
http://www.ama-assn.org/go/cpt2022  4293FPatient screened for high-risk sexual behavior (HIV)
http://www.ama-assn.org/go/cpt2022  86689Antibody; HTLV or HIV antibody, confirmatory test (eg, Western Blot)
http://www.ama-assn.org/go/cpt2022  86701Antibody; HIV-1
http://www.ama-assn.org/go/cpt2022  86702Antibody; HIV-2
http://www.ama-assn.org/go/cpt2022  86703Antibody; HIV-1 and HIV-2, single result
http://www.ama-assn.org/go/cpt2022  87389Infectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]), qualitative or semiquantitative; HIV-1 antigen(s), with HIV-1 and HIV-2 antibodies, single result
http://www.ama-assn.org/go/cpt2022  87390Infectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]), qualitative or semiquantitative; HIV-1
http://www.ama-assn.org/go/cpt2022  87391Infectious agent antigen detection by immunoassay technique (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]), qualitative or semiquantitative; HIV-2
http://www.ama-assn.org/go/cpt2022  87534Infectious agent detection by nucleic acid (DNA or RNA); HIV-1, direct probe technique
http://www.ama-assn.org/go/cpt2022  87535Infectious agent detection by nucleic acid (DNA or RNA); HIV-1, amplified probe technique, includes reverse transcription when performed
http://www.ama-assn.org/go/cpt2022  87536Infectious agent detection by nucleic acid (DNA or RNA); HIV-1, quantification, includes reverse transcription when performed
http://www.ama-assn.org/go/cpt2022  87537Infectious agent detection by nucleic acid (DNA or RNA); HIV-2, direct probe technique
http://www.ama-assn.org/go/cpt2022  87538Infectious agent detection by nucleic acid (DNA or RNA); HIV-2, amplified probe technique, includes reverse transcription when performed
http://www.ama-assn.org/go/cpt2022  87539Infectious agent detection by nucleic acid (DNA or RNA); HIV-2, quantification, includes reverse transcription when performed
http://www.ama-assn.org/go/cpt2022  87900Infectious agent drug susceptibility phenotype prediction using regularly updated genotypic bioinformatics
http://www.ama-assn.org/go/cpt2022  87901Infectious agent genotype analysis by nucleic acid (DNA or RNA); HIV-1, reverse transcriptase and protease regions
http://www.ama-assn.org/go/cpt2022  87903Infectious agent phenotype analysis by nucleic acid (DNA or RNA) with drug resistance tissue culture analysis, HIV 1; first through 10 drugs tested
http://www.ama-assn.org/go/cpt2022  87904Infectious agent phenotype analysis by nucleic acid (DNA or RNA) with drug resistance tissue culture analysis, HIV 1; each additional drug tested (List separately in addition to code for primary procedure)
http://www.ama-assn.org/go/cpt2022  87906Infectious agent genotype analysis by nucleic acid (DNA or RNA); HIV-1, other region (eg, integrase, fusion)

Explanation of the columns that may appear on this page:

Level A few code lists that FHIR defines are hierarchical - each code is assigned a level. In this scheme, some codes are under other codes, and imply that the code they are under also applies
System The source of the definition of the code (when the value set draws in codes defined elsewhere)
Code The code (used as the code in the resource instance)
Display The display (used in the display element of a Coding). If there is no display, implementers should not simply display the code, but map the concept into their application
Definition An explanation of the meaning of the concept
Comments Additional notes about how to use the code

History

DateActionAuthorVerifierComment
2023-01-31reviseJohn MoehrkeAdministrative touchup to add history
2022-07-27createJohn MoehrkeJohn F. MoehrkeInitial ValueSet as per the C2S layout